Studies immune and metabolic changes in fatty liver disease
Compares immune cells, blood markers and gut bacteria in adults with fatty liver disease.
Plain-language title generated from the registry record
Registry title: Investigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease
Key facts
- Where
- London, United KingdomSee the site
Where in United Kingdom
- Homerton University Hospital Foundation TrustLondon, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Queen Mary University of London
- Trial code
- NCT04141592
- Record updated
- 5 June 2026
- Original description
To identify key characteristics of the tissue resident and peripherally circulating immune-phenotype in addition to blood markers, metabolic profile, faecal and oral microbiota in non-alcoholic fatty liver diseaseRead full original descriptionShow less
Investigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease: Cross-sectional Comparative Study Between Patients and Healthy Controls
To identify key characteristics of the tissue resident and peripherally circulating immune-phenotype in addition to blood markers, metabolic profile, faecal and oral microbiota in non-alcoholic fatty liver disease
Inclusion: Age ≥18 years; Confirmed non-alcoholic Fatty liver disease (diagnosed clinically, radiologically or histologically); If diabetic, Diagnosed with Type 2 Diabetes Mellitus; OR; Healthy Control: no diagnosis of any liver condition including NAFLD; o NAFLD excluded by Fibroscan Controlled Attenuation Parameter (CAP) score of <222 dB/m.
Exclusion: Taking medication associated with liver dysfunction (except methotrexate); Concomitant immunosuppressive medications (except methotrexate, short course oral steroids or inhaled corticosteroids); Any major organ transplant (excluding corneal or hair transplant); Type 1 Diabetes Mellitus; Other form of liver disease (other than NAFLD); o Viral hepatitis, Auto-immune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis, haemochromatosis, Sarcoidosis, cystic fibrosis, sickle cell disease; Auto-immune disease which in the investigator's opinion may confound immune profiling; Unwilling or unable to give informed consent; Currently pregnant; Regular alcohol intake greater than 14 units a week for female participants and 21 units a week for male participants.